Medication adherence and, potentially, improved outcomes are associated with treatment satisfaction.

ARTEMIS-2/P261-402 (NCT01529034) was a Phase III, open-label extension trial in patients (≥12 years) with seizure clusters (SCs). Caregivers administered MDZ-NS 5 mg when patients experienced a SC; a second dose could be given if seizures did not end within 10 min or recurred within 6 h post MDZ-NS administration. Patient satisfaction with MDZ-NS was assessed with Treatment Satisfaction Questionnaire for Medication (TSQM), and patient and caregiver perceptions of how having access to MDZ-NS might impact their lives with Intranasal Therapy Impact Questionnaire (ITIQ). Patients and caregivers completed questionnaires at each visit (after one treated SC after Visit [V]1 and V2, and after two treated SCs thereafter). Analyses were exploratory.

161/175 enrolled patients (92.0%) were evaluable. All TSQM scales showed improvement from Baseline at Last Visit (mean change 4.3–8.8; p<0.05 to <0.001). Mean change from Baseline showed a tendency to improve at V1–V10 for all TSQM scales except side-effects; improvement generally increased over repeated MDZ-NS use for all scales. Mean change in anxiety level since receiving MDZ-NS (ITIQ) improved from 2.5 (standard deviation 2.5) (V1) to 3.5 (2.7) (Last Visit) in patients and from 2.6 (2.5) to 3.6 (2.7) in caregivers, and generally improved over repeated MDZ-NS use. Proportions of patients and caregivers who answered ‘strongly agree’ or ‘agree’ for confidence about traveling with an intranasal spray was ≥79% throughout and rose from V1–V10.

Patients perceived MDZ-NS as a favorable therapy: perceived effectiveness, side-effects, convenience, and global satisfaction showed improvement from Baseline. This is supported by improvement in anxiety level and consistently high confidence about traveling with MDZ-NS in patients and caregivers over repeated intermittent use.